Nevertheless, this evidence is based on very rare findings given that HER2 activating mutations are described to occur in less than 2% of breast cancer, with a higher frequency in HR-positive compared to TNBC and in lobular than in ductal histology (Exman et al., 2019). The gene discussed is ERBB2; the disease is breast carcinoma.